Multicenter collaborative study to determine safety, tolerance and efficacy of human anti-CMV monoclonal antibody in the treatment of neonates with congenital symptomatic CMV infection but without CNS disease.
Specific aim i s to determine if the drug will decrease mortality, improve rate of growth, BSER and resolution of retinitis, and reverse hematologic abnormalities. The drug will be given IV in 3 doses q 2 wks for 6 wks. Results will be pooled and analyzed with data from other centers as part of the NIAID antiviral study group sponsored study.
Showing the most recent 10 out of 465 publications